Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
With
Gilero, LLC
Primary Objectives:
1. Establish feasibility of topical vapocoolant in the setting of breast lymphoscintigraphy.
2. Demonstrate safety of topical vapocoolant in the setting of breast lymphoscintigraphy.
Secondary Objectives:
1. To assess patient pain intensity associated with the performance of breast lymphoscintigraphy.
2. To evaluate the attitude from patients about supporting the continued offering of topical vapocoolant in the breast lymphoscintigraphy clinic.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any adult patient undergoing asubareolar breast lymphoscintigraphy injection will be eligible.
Age ≥18 years old
Ability to understand and the willingness to sign a written informed consent document.
Childbearing potential, lactating, pregnant women will be included.
You may not be if
Patients who have allergy or had prior hypersensitivity to either of the vapocoolants including 1,1,1,3,3 Pentafluoropropane and 1,1,1,2-Tetrafluoroethane.
Patients with uncontrolled intercurrent illness (insulin dependent and non-insulin dependent diabetes)
Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Clareo Health | Vapocoolant Analgesia for Breast Lymphoscintigraphy
